ArticleJPGN reports2026
Liver stiffness in patients with Shwachman-Diamond syndrome.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: This case series aims to describe whether transient elastography (TE) as a marker of liver stiffness is associated with clinically important liver disease in children and young adults with Shwachman-Diamond Syndrome (SDS). Methods: All patients ≤25 years of age with genetically confirmed SDS seen in the Pediatric Gastroenterology Clinic at Boston Children's Hospital from 07/2017 to 11/2019 were included. Data collected included TE, hepatic transaminases, fecal elastase, and anthropometry. The correlation of liver stiffness measurements with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was assessed by Spearman rank correlation accompanied by 95% confidence intervals based on Fisher's Results: Eight patients (six female) were identified with genetically confirmed SDS for whom the median age on the day of TE was 6years. Median (range) AST and ALT were 31 U/L (17-61) and 30 U/L (12-87), respectively, obtained within a median of 18 days (range 0-168) from liver stiffness measurement (LSM). All patients had exocrine pancreatic insufficiency as defined by fecal elastase <200 μg/g. Five patients had abdominal ultrasound within a median of 1.7 years (range 0.0-5.1), of whom four had normal results (one unknown). All eight patients underwent TE with median (range) LSM and controlled attenuation parameter (CAP) measurement ( Conclusion: In our case series of eight patients with SDS, LSM greater than METAVIR F0 was reported in three patients, two of whom had normal transaminases. This suggests that subclinical liver disease may exist in SDS patients with normal hepatic transaminases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.